Floatz logo

141 assets in Hodgkins Lymphoma

Therapeutic assets addressing Hodgkins Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
hcb301
Hodgkins Lymphoma
FBD Biologics LimitedP1CC (43)
Lcar-Hl30 Cells
Hodgkins Lymphoma
Ruijin HospitalP1CC (43)
Mabel Ctls
Hodgkins Lymphoma
Baylor College of MedicineP1CC (43)
PF-08046044
Hodgkins Lymphoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
pf-08046045
Hodgkins Lymphoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
Sgn-35
Hodgkins Lymphoma
Seagen, a wholly owned subsidiary of PfizerP1CC (43)
Tgfbeta Resistant Lmp-Specific Ctls
Hodgkins Lymphoma
Baylor College of MedicineP1CC (43)
Venetoclax
Hodgkins Lymphoma
Children's Hospital Medical Center, CincinnatiP1CC (43)
azd3470
Hodgkins Lymphoma
AstraZenecaP1/2CC (41)
Car.70/Il15-Transduced Cb-Nk Cells
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP1/2CC (41)
Cobolimab
Hodgkins Lymphoma
GlaxoSmithKlineP1/2CC (41)
Cytokine-Treated Veto Cells
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP1/2CC (41)
Dostarlimab
Hodgkins Lymphoma
GlaxoSmithKlineP1/2CC (41)
Fruquintinib
Hodgkins Lymphoma
Immunitas TherapeuticsP1/2CC (41)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated
Hodgkins Lymphoma
Immunitas TherapeuticsP1/2CC (41)
Bms-986345
Hodgkins Lymphoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (40)
Duvelisib
Hodgkins Lymphoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (40)
Nadravaleucel
Hodgkins Lymphoma
David WaldP1CC (40)
aur105
Hodgkins Lymphoma
Aurigene Discovery Technologies LimitedP1C (37)
BP1002
Hodgkins Lymphoma
Bio-Path Holdings, Inc.P1C (37)
c7r.cd30.car-ebvst cells
Hodgkins Lymphoma
Baylor College of MedicineP1C (37)
Cart-45 Cells
Hodgkins Lymphoma
University of PennsylvaniaP1C (37)
cd45be-hspc
Hodgkins Lymphoma
University of PennsylvaniaP1C (37)
Ctx-8371
Hodgkins Lymphoma
Compass TherapeuticsP1C (37)
Dextromethorphan
Hodgkins Lymphoma
Murdoch Childrens Research InstituteP1C (37)
il-15 enhanced engineered nk cells
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP1C (37)
jlm019
Hodgkins Lymphoma
Jecho Biopharmaceuticals Co., Ltd.P1C (37)
Neldaleucel
Hodgkins Lymphoma
Marker Therapeutics, Inc.P1C (37)
Omeprazole
Hodgkins Lymphoma
Murdoch Childrens Research InstituteP1C (37)
Pediatric Multitaa T Cells Stage
Hodgkins Lymphoma
Baylor College of MedicineP1C (37)
Taa-Specific Ctls
Hodgkins Lymphoma
Baylor College of MedicineP1C (37)
Tagraxofusp
Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia ConsortiumP1C (37)
Tgfbr2 Ko Car27/Il-15 Nk Cells
Hodgkins Lymphoma
M.D. Anderson Cancer CenterP1C (37)
Vactosertib
Hodgkins Lymphoma
David WaldP1C (37)
Zoledronate
Hodgkins Lymphoma
University of Wisconsin, MadisonP1C (37)
Magrolimab
Hodgkins Lymphoma
Ranjana AdvaniP2C (36)
Anti Cd30 Car-T Cell
Hodgkins Lymphoma
Zhejiang UniversityEarly P1C (34)
Hyaluronidase Fihj
Hodgkins Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEarly P1C (34)
Penpulimab
Hodgkins Lymphoma
AkesoP3NR ()
Showing 101 to 141 of 141 assets
PreviousPage 3 of 3Next